迈向T细胞受体疗法的实体瘤综合解决方案:综述
本综述总结了T细胞受体疗法(TCR-T)在实体瘤中的临床应用与优势,探讨了亲和力、药代动力学/药效学及适应症等疗效/安全性相关参数,并基于RNA-seq数据集重新审视肿瘤抗原表达以提高实体瘤覆盖率,最后讨论了当前局限与未来方向。
要点
- TCR-T在HPV相关肿瘤、滑膜肉瘤和黑色素瘤等实体瘤中显示疗效、持久性和安全性优势。
- 综述探讨了亲和力、药代动力学/药效学及适应症等疗效/安全性相关参数。
- 基于RNA-seq数据集重新审视肿瘤抗原表达,以探索提高实体瘤覆盖率的可能。
核心结论
- TCR-T在部分实体瘤中已显示疗效、持久性和安全性优势,本综述为实体瘤TCR-T开发提供了需要仔细考虑的要点。
研究设计与样本
- 本综述总结了TCR-T在实体瘤中的当前临床应用、TCR-T模式的优点,并探讨了疗效/安全性相关参数。
主要发现
- TCR-T在HPV相关肿瘤、滑膜肉瘤和黑色素瘤等某些实体瘤中显示出疗效、持久性和安全性优势。
- 综述探讨了亲和力、药代动力学/药效学及适应症等疗效/安全性相关参数。
- 综述考察了与亲和力相关的关键因素,包括抗原选择、T细胞受体获取、优化和共受体结合。
- 综述基于当前RNA-seq数据集重新审视了肿瘤抗原表达,以探索实体瘤潜在更高的覆盖率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell receptor therapy (TCR-T) has demonstrated efficacy, durability, and safety advantages in certain solid tumors (such as human papillomavirus-related tumors, synovial sarcoma, and melanoma). This study aimed to provide careful considerations for developing TCR-T for solid tumors. Therefore, in this review, we have summarized the current clinical application, advantage of TCR-T modalities and explored efficacy/safety-related parameters, particularly avidity, pharmacokinetics/pharmacodynamics, and indications, for solid tumors. Furthermore, we have investigated critical factors related to avidity, including antigen selection, T-cell receptor acquisition, optimization, and co-receptor engagement. Moreover, we have re-examined the expression of tumor antigens for a potentially higher coverage rate of solid tumors based on the current RNA-seq datasets. Finally, we have discussed the current limitations and future directions of TCR-Ts.
引用
- Ma P, Jiang Y, Zhao G, et al. Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review. Eur J Cancer. 2024. PMID: 39067370. doi:10.1016/j.ejca.2024.114224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。